| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a protected amino acid derivative, H-Lys(Z)-OMe.HCl does not have a specific pharmacological target. Its primary role in research is as a chemical building block rather than a biologically active compound. However, upon deprotection, the resulting lysine derivative can interact with amino acid transporters, including the cationic amino acid transporter (CAT) family and system y⁺ transporters, which mediate cellular uptake of basic amino acids. The compound may also serve as a substrate for enzymes involved in amino acid metabolism and protein synthesis in cell culture applications.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies have shown that amino acid derivatives like H-Lys(Z)-OMe.HCl influence the release of anabolic hormones and affect the availability of fuel for cellular activity. Research indicates that lysine derivatives can support cell viability and proliferation in various culture systems. The compound has been investigated for its effects on protein metabolism and cellular energy homeostasis. Studies suggest that amino acid derivatives are regarded as advantageous synergistic food ingredients, potentially enhancing the effects of other nutrients. However, as a protected amino acid, the biological activity of H-Lys(Z)-OMe.HCl itself is limited until the protecting groups are removed. |
| ln Vivo |
In vivo studies on protected amino acid derivatives are limited, as these compounds are typically used as synthetic intermediates rather than as bioactive agents. When administered to animals, the protecting groups may be cleaved by esterases and other metabolic enzymes, releasing the active lysine. Research in rodent models has shown that lysine supplementation can influence growth performance, nitrogen balance, and immune function. Amino acid derivatives have been studied for their potential to improve mental performance under stress and prevent exercise-induced muscle damage. However, H-Lys(Z)-OMe.HCl specifically has limited published in vivo data.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for protected amino acid derivatives typically focus on their interaction with proteolytic enzymes and esterases that cleave the protecting groups. A standard protocol involves incubating the compound with trypsin, chymotrypsin, or other proteases in appropriate buffer systems (e.g., 50 mM Tris-HCl, pH 8.0) at 37°C. The release of free lysine or methyl ester is monitored using HPLC or mass spectrometry. For peptidase assays, fluorogenic substrates may be used to measure enzyme activity. Binding to amino acid transporters can be assessed using radiolabeled competition assays with cell membrane preparations expressing specific transporters.
|
| Cell Assay |
In vitro cellular assays for H-Lys(Z)-OMe.HCl typically involve cell lines such as HEK293, CHO, or primary cell cultures to evaluate the compound's effects on cellular metabolism and protein synthesis. A common protocol involves seeding cells in multi-well plates at appropriate densities and incubating overnight at 37°C with 5% CO₂. Cells are then treated with varying concentrations of the compound (typically 1-1000 µM) for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or resazurin-based assays. The compound may be evaluated for its effects on gene expression, protein production, and metabolic pathways using qPCR, Western blotting, or metabolomics approaches.
|
| Animal Protocol |
In vivo animal studies with protected amino acid derivatives typically utilize rodent models such as rats or mice. A standard protocol involves administration via oral gavage, intraperitoneal, or intravenous injection at doses ranging from 10-200 mg/kg body weight. Animals are maintained under standard laboratory conditions. Blood samples are collected at predetermined time points for pharmacokinetic analysis. Tissue distribution studies may be performed to evaluate the compound's accumulation in organs. Metabolic studies assess the conversion of the protected derivative to active lysine. Behavioral studies may evaluate effects on cognitive function or exercise performance.
|
| ADME/Pharmacokinetics |
H-Lys(Z)-OMe.HCl (molecular weight 247.16 g/mol) exhibits moderate lipophilicity with a LogP of 3.01. The compound is soluble in aqueous solutions and organic solvents. As a methyl ester, it is susceptible to hydrolysis by esterases in vivo, releasing the free acid form. The Z-protecting group is cleaved by hydrogenolysis or by strong acids. The compound has a melting point of approximately 150°C (dec.). The hydrochloride salt form enhances aqueous solubility and stability. Following absorption, the compound undergoes metabolic cleavage of protecting groups, followed by normal amino acid metabolism and renal excretion.
|
| Toxicity/Toxicokinetics |
The hydrochloride salt of H-Lys(Z)-OMe exhibits low toxicity, consistent with its nature as an amino acid derivative. The compound should be handled with standard laboratory precautions. Acute toxicity is expected to be low, with an oral LD₅₀ in rodents likely >2000 mg/kg based on similar compounds. The compound is not considered genotoxic or carcinogenic. Skin and eye contact may cause mild irritation. Inhalation of dust should be avoided. The compound is stable under normal storage conditions. No significant environmental hazards have been reported.
|
| References | |
| Additional Infomation |
See also: L-lysine ethyl ester hydrochloride (note moved to).
H-Lys(Z)-OMe.HCl is a white to off-white solid powder. The compound has a boiling point of 261.9°C at 760 mmHg and a flash point of 97.3°C. It should be stored as a powder at -20°C for up to 3 years, at 4°C for up to 2 years, and in solution at -80°C for 6 months or -20°C for 1 month. The compound is supplied with ≥98% purity. It is for research use only and is not approved for human therapeutic applications. Common applications include peptide synthesis, medicinal chemistry, and biochemical research. |
| Molecular Formula |
C8H20CL2N2O2
|
|---|---|
| Molecular Weight |
247.1626
|
| Exact Mass |
246.09
|
| CAS # |
3844-53-9
|
| PubChem CID |
107468
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
261.9ºC at 760 mmHg
|
| Melting Point |
~150 °C (dec.)
|
| Flash Point |
97.3ºC
|
| LogP |
3.01
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
14
|
| Complexity |
128
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
Cl[H].Cl[H].O(C([H])([H])C([H])([H])[H])C([C@]([H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])N([H])[H])=O
|
| InChi Key |
DZIYAIZKJOHVQC-KLXURFKVSA-N
|
| InChi Code |
InChI=1S/C8H18N2O2.2ClH/c1-2-12-8(11)7(10)5-3-4-6-9;;/h7H,2-6,9-10H2,1H3;2*1H/t7-;;/m0../s1
|
| Chemical Name |
ethyl (2S)-2,6-diaminohexanoate;dihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0460 mL | 20.2298 mL | 40.4596 mL | |
| 5 mM | 0.8092 mL | 4.0460 mL | 8.0919 mL | |
| 10 mM | 0.4046 mL | 2.0230 mL | 4.0460 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
